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August 2011582 Abstractsthe clinical strength and statistical significance of IMT changes associated
with cardiovascular outcomes when compared tomore direct atherosclerotic
risk factors. It may also be, that atherosclerosis in the carotid artery, is not
generally representative of atherosclerosis throughout the body. Atheroscle-
rotic plaques in the carotid artery grow longitudinally at twice the rate that
they grow in thickness. Therefore, IMT may be a less sensitive measure of
plaque evolution than total plaque burden (Mackinnon AD, et al. Stroke
2004;35:2150-4). The bottom line, however, is that while IMT increase
indicates increased cardiovascular risk, changes in IMT induced by drug
therapy do not appear to reflect clinical outcome.
Outcomes of Endovascular Repair of Ruptured Descending Thoracic
Aortic Aneurysms
Jonker FH, Verhagen HJ, Lin PH, et al. Circulation 2010;121:2718-23.
Conclusions: Endovascular repair of ruptured descending thoracic
aortic aneurysms (TAAs) provides encouraging results but is associated with
a significant rate of neurologic complications and a relatively high rate of
endoleak.
Summary: Ruptured TAAs are relatively rare with reported an inci-
dence of only about 5 per 100,000. Mortality is high and is thought to
exceed 90% (Johannson G. J Vasc Surg 1995;21:985-8). There is little
information on endovascular treatment of ruptured TAAs. Ruptures of true
degenerative TAAs are often lumped in other series combining penetrating
aortic ulcers, thoracic aortic trauma and complications of type B dissection.
The authors accumulated a “pure” series of ruptured descending TAAs by
identifying patients treated with endovascular repair for ruptured AA at 7
different centers between July 2002 and July 2009. There were 87 patients
in this retrospective study with a mean age of 69.8  12 years and 69.0%
were men. At presentation 40.2% were hemodynamically unstable and
21.8% were in hypovolemic shock. Following endovascular repair mortality
was 18.4%. Increased 30-day mortality after adjusting for age, was associated
with hypovolemic shock (OR, 4.75; 95% CI, 1.37 to 16.5; P  .014) and
hemothorax on admission (OR, 6.65; 95% CI, 1.64 to 27.1; P  .008).
Ruptured TAA s were successfully excluded during TEVAR in 95.4%. Stroke
occurred in 8% (n  7). Four patients died of stroke. Post operative
paraplegia occurred in 8% (n  7) and was permanent in 2 patients and
transient in 5. There was an 18.4% incidence of endoleak during the first 30
days (n  16) with type 1 of endoleaks occurring in 10 patients, type 2
endoleaks in 5 patients and a type 3 endoleak in one patient. There were 2
late aortic esophageal fistulas that were fatal. Estimated freedom from
aneurysm related death or intervention was 54.9% at 4 years.
Comment: Short term mortality rates of TEVAR treatment of de-
scending TAA rupture compares favorably with open repair of descending
TAA rupture (Schermerhorn ML, et al. J Vasc Surg 2008;48:821-7).
Endovascular repair of a descending ruptured TAA does appear to be
associated with a high rate of neurologic and procedurally related complica-
tions, particularly type 1 endoleak. The data make it reasonably to consider
TEVAR for repair of a ruptured descending TAA but morbidity and mor-
tality are still significant.
Risk of Early Carotid Endarterectomy for Symptomatic Carotid
Stenosis
Brinjikji W, Rabinstein AA, Meyer FB, et al. Stroke 2010;41:2186-90.
Conclusion: Carotid endarterectomy (CEA) can be performed with
slightly increased, but acceptable, risk in symptomatic patients within two
weeks of stroke or transient ischemic attack.
Summary:Current guidelines from the American Academy of Neurol-
ogy and the American Heart Association indicate patients with symptomatic
carotid stenosis should preferentially undergo CEA within 2 weeks of the
symptomatic event (Chaturvedi S, et al. Neurology 2005;65:794-801, and
Sacco RL, et al. Stroke 2006;37:577-617). However many patients are not
operated within 2 weeks. In addition, traditional “surgical wisdom” has
shied away from acute operation especially in stroke patients for fear of a
higher incidence of complications (Naylor AR. Surgeon 2007;5:23-30).
The authors examined their institutional experience with CEA with
particular analysis of symptomatic patients operated within 2 weeks of
symptoms. Symptomatic patients were not considered for early CEA if they
had an infarct involving more than one third of the middle cerebral artery
territory or if a patient had a fixed disabling deficit or an unstable medical
condition. When those conditions were not present patients were operated
soon after evaluation irrespective of the interval from the symptomatic event.
The authors felt delays were usually related to delayed referral after symptom
onset.
The patients analyzed were those operated between January 2004 and
May 2009. Patients were divided into three groups. Group 1 were asymp-
tomatic, group 2 were symptomatic patients operated 2 weeks after their
symptom, and group 3 were symptomatic patients operated on 2 weeks
after their symptom (transient ischemic attack or stroke). Primary outcome
was any myocardial infarction, stroke, or death within 30 days of the
c
operation. A secondary endpoint was transient ischemic attack within 30
ays postoperatively.
There were 532 carotid endarterectomies performed in 507 patients.
here were 500 patients with 525 CEA’s who had 30 day follow up. There
ere 278 in group 1, 105 in group 2, and 142 in group 3. The primary
utcome occurred in 5 patients in group 1 (1.8%); 1 patient in group 2
1.0%); and 6 patients in group 3 (4.2%). There were no significant differ-
nces in the rate of primary outcome among the three groups (P  .17).
here was also no significant difference comparing group 2 to group 3 (P
24).
Comment: This study has all the limitations of a single institution
etrospective review. The biggest problem is insuring patients in group 2 and
roup 3 did in fact only differ primarily by referral pattern and not by other
ore pertinentmedical conditions. The percentage of patients with stroke in
roup 2 and group 3 was similar (36.2% versus 35.2%), but we really don’t
now whether the severity of the strokes were the same and whether
erioperative management and other co-morbidities were the same. Never-
heless, this study lends further support to a policy of performance of CEA in
elected patients shortly after the onset of a neurologic symptom.
uperior Nationwide Outcomes of Endovascular versus Open Repair
or Isolated Descending Thoracic Aortic Aneurysm in 11,669 Patients
opaldas RR, Huh J, Dao TK, et. al. J Thorac Cardiovas Surg 2010;140:
001-10.
Conclusion: Compared with open aortic repair (OAR) thoracic endo-
ascular aneurysm repair (TEVAR) is associated with shorter hospital stay,
imilar mortalities, fewer complications, and increased hospital charges.
Summary: The first endovascular prosthesis was approved in 2005 for
horacic endovascular aneurysm repair in the United States. The technology
as been widely adopted but there is little information available on TEVAR
ationwide outcomes for treatment of descending isolated thoracic aortic
neurysm (TAA). The authors therefore compared in hospital outcomes of
EVAR and open descending TAA repairs performed in the United States
uring the initial 3 years following approval of the GORETAG device. They
sed nationwide data to identify patients who had undergone surgery for
solated descending TAA from 2006-2007. Patients treated for aortic dis-
ection or rupture or who underwent simultaneous treatment of other aortic
egments were excluded. There were 11,669 patients analyzed and 9,106
ad conventional open aneurysm repair (OAR) and 2,563 had TEVAR.
atients were compared for mortality and hospital stay as well as discharge
tatus, morbidity, and hospital charges.
Patients undergoing TEVAR were older (69.5  12.7 versus 60.2 
4.2 years; P .001) and had higher preoperative morbidity. Length of stay
as shorter for TEVAR patients (7.7  11 versus 8.8  7.9 days). Unad-
usted mortality was similar for TEVAR (2.3%) and OAR (2.2%; P  1.0).
here were similar proportions of non elective interventions in the two
roups (TEVAR 15.9% versus OAR 15.8%; P .9). Risk adjusted mortality
ates with TEVAR and OAR were similar. TEVAR patients, however, had
0% fewer complications (OR, 0.39; P  .001). TEVAR patients were 4
imes more likely to have a routine discharge home than OAR patients.
EVAR hospital charges were greater by $6713 (95% CI, 1869- 11,556;
 .001).
Comment: Surgical procedures with good outcomes and that are
easy” to perform are adopted widely. More difficult procedures are gener-
lly restricted to high volume centers. Wide spread adoption of TEVAR is
ppropriate. Even though TEVAR was selectively performed in patients
lmost a decade older than the OAR patients, outcomes were comparable, if
ot superior, for TEVAR versus OAR with TEVAR having significantly
etter risk adjusted morbidity, primarily from lower incidences of neuro-
ogic, respiratory and pulmonary complications. Additional data is needed to
etermine whether TEVAR has volume dependent outcomes, or like endo-
ascular abdominal aortic aneurysm repair, can be performed with relatively
ow morbidity in low volume hospitals. Such data is needed to determine
hether thoracic aortic aneurysm patients should be treated in centers
edicated to treatment of aortic disease or if TEVAR will permit more wide
pread treatment of thoracic aortic pathology in community and smaller
egional hospitals.
iming of Preoperative Beta-Blocker Treatment in Vascular Surgery
atients Influence on Postoperative Outcome
lu WJ, van Kujik JP, Chonchol M, et.al. J Am Coll Cardiol 2010;56:
922-9.
Conclusion: -blocker treatment initiated more than one week before
ascular surgery is associated with lower preoperative heart rate and im-
roved cardiovascular outcomes compared to treatment initiated less than
ne week preoperatively.
Summary:Most randomized control trials and observational studies of
-blocker therapy in vascular surgical patients indicate a favorable effect on
ardiovascular outcome with perioperative -blockers. Benefit may be sec-
ndary to heart rate control, reduction of systolic pressure, reduction in
